RCKT
Rocket Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +14.2% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 115.40K | $303,509 | n/a | n/a |
| Q2 2026 | 80 | -1 | 55.09M | $188.40M | +4 | −5 |
| Q1 2026 | 83 | +2 | 57.14M | $204.44M | +8 | −6 |
| Q4 2025 | 81 | +2 | 51.01M | $179.05M | +2 | n/a |
| Q3 2025 | 15 | 0 | 38.20M | $124.54M | n/a | n/a |
| Q2 2025 | 12 | -1 | 25.35M | $62.12M | +2 | −3 |
| Q1 2025 | 10 | -1 | 24.61M | $164.16M | +1 | −2 |
| Q4 2024 | 11 | 0 | 29.17M | $366.63M | +1 | −1 |
| Q3 2024 | 10 | 0 | 19.68M | $363.43M | +2 | −2 |
| Q2 2024 | 10 | n/a | 17.23M | $370.95M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 11.24M | +22.8% | $207.64M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 2 | T. Rowe Price ✦ | 3.21M | +1.2% | $59.25M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 2.15M | -23.8% | $39.68M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passive) | 1.62M | +0.9% | $29.89M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 1.20M | +1041.7% | $22.21M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 159.09K | +357.8% | $2.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 48.10K | New | $888,331 | 0.0% | New | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 21.82K | -5.5% | $402,942 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 18.91K | New | $349,231 | 0.0% | New | 1 | SEC ↗ ×2 |
| 10 | Marshall Wace ✦ | 10.10K | -48.4% | $186,547 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $888,331 | 0.0% |
| AQR Capital Management | $349,231 | 0.0% |
Exited
| Adage Capital Partners | $4.31M | was 0.0% |
| Renaissance Technologies | $2.14M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 195 holders, 96.37M shares, $341.40M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 75.36K sh · $256,464
Officer · 2.29K sh · $7,753
Officer · 631 sh · $2,133
Officer · 4.70K sh · $16,449
Officer · 36.66K sh · $128,266
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology